BioTOPics 46 | September 2013
BioTOP-Report
Editorial
Unique Chances to Create Value in Biotechnology and Life Sciences
3
Biotechnology
More Companies, More Employees and New Deals
4
Pharma
The German Capital Region: Highly Attractive for the Pharmaceutical Industry
14
Diagnostics
An Excellent Location for the Development of Innovative Diagnostics
18
Industrial Biotechnology
Focus: Biopolymers and Bio-based Plastics
22
Global Business
New Markets and Horizons for Global Business
25
Business Location
Excellent Services for Berlin-Brandenburg
28
Technology Transfer
Technology Transfer
between Science and Business
30
Life Sciences
A Science and Research Hub
34
Know-how in Systems Medicine and Systems Biology
36
Biotech 2020+
41
Biotech Parks
The BioCampus Network Berlin-Brandenburg
50
Addresses
55
Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-Brandenburg
Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · biotop@biotop.de · www.healthcapital.de
Editor: Yvonne Küchler
Design & Production: supiran.de
Translation: Textbüro Reul GmbH · Frankfurt
Photos/Figures: BioTOP or Authors and:
Page 10 Ralfpoller*, Wladimir Bulgar*; Page 13 Werner Popp (Profile organobalance), Vanillla * (Profile BPI); Page 14 Phartisan*, Idrutu*; Page 18 Stratum*,
Stanislav Perov*; Page 20 Alx, fotolia.com (Profile Dr. Nothgi); Page 22 BASF; Page 25 C. Keating*, Moth*; Seite 32 Bayer HealthCare; Page 33 Eric1513*,
Jankaliciak*, Grafoo*, Eraxion*, Kjpargeter*, Andrey Armyagov*; Page 37 Christoph Heidrich; Page 40 Illustration: webersupiran, photo Sofiaworld *;
Page 41 Paulus Rusyanto*, Collpicto*, 18percentgrey*; Page 46 Natalia Pavlichenko*/Patho (Profile Predemtec)
*dreamstime.com
Content
3
BioTOPics 46 | September 2013
BioTOP-Report
Editorial
The German Capital Region – Unique Chances to
Create Value in Biotechnology and Life Sciences
In an emerging health environment, manufacturers of drugs, diagnostics and devices will need to be able to
prove not only the safety and efficacy but also the value of their products. Thus all players in the value chain –
reaching from scientific institutions and biotech companies to clinics and healthcare providers – are rethinking
their products, services and business models. They find perfect conditions in Berlin-Brandenburg.
Obviously, most participants in the value chain have realised that
cooperation is the most important factor for success and are shap-
ing their cooperation strategies:
k
Cross-innovation at the interface of life sciences, information
technology and engineering takes place everywhere. This
innovation sector will not only create value through new tools
and cost reduction in healthcare delivery, but also enable
all of us to take control of our own health and wellness. The
most recent example is the Joint Lab for Bioelectronics of
the Technische Universität Berlin and the Leibniz Institute for
Microelectronics.
k
Basic and clinical research of the Max Delbrück Center of
Molecular Medicine (MDC) and the Charité – Universitäts-
medizin Berlin will come together in the Berlin Institute of
Health (BIH) to create the new flagship of German life sci-
ences.
k
Scientific excellence and development experience will team
up in the CoLaborator, established by Bayer to incubate start-
ups.
k
Entrepreneurial skills will be strengthened in the Entrepre-
neurial Network University of the Freie Universität Berlin,
Charité and several companies.
Berlin-Brandenburg is indeed the European hotspot for collab-
oration. More than 200 biotechnology and 30 pharmaceutical
companies benefit from close cooperation with five universities
and more than a dozen institutes of the Helmholtz, Max Planck,
Fraunhofer and Leibniz societies and associations, as well as
more than 130 hospitals – among them Europe’s largest univer-
sity hospital: Charité – Universitätsmedizin Berlin.
As a consequence, the sector has grown more than 6% in 2012
and is growing continuously since 10 years. This fertile ground
will be further strengthened with the new master plan for the
healthcare industry. BioTOP is pleased to present the most im-
portant developments in life sciences, pharma and biotechnology
in our new annual report.
We hope you enjoy reading our report, and we invite you to play
an active role in one of the most vibrant European life sciences
networks. Don’t hesitate to contact us.
Dr. Kai Bindseil
Dr. Kai Bindseil
Cluster Manager HealthCapital
Director BioTOP Berlin-Brandenburg
bindseil@biotop.de
www.healthcapital.de
4
BioTOPics 46 | September 2013
BioTOP-Report
Biotechnology
More Companies, More Employees and New Deals
The positive development of the regional corporate landscape got new momentum in 2012. The number of
employees in the sector rose by 6.5 %. Compared to average growth rates of 3.5% during recent years, this has
been a clear and very welcome sign of the dynamism in the Berlin-Brandenburg region, where 222 companies
now employ a workforce numbering 4,348 people.
Development of the Companies in 2012
BioTOP conducted its anual survey of regional companies for the
year 2012 to obtain a comprehensive overview of the current
development of the corporate scene. During 2012, twelve new
companies joined the ranks of surveyed companies, of which
nine were newly founded and three included in the survey for
the first time. Five companies ceased operations or moved to a
different region. The new companies are still smaller firms focus-
ing on services and product development in the field of biomed-
icine. As an example, we refer to t-cell Europe, which received
funding from the High-Tech Gründerfonds (HTGF). The aim of
t-cell Europe, a spin-off of the Berlin-Brandenburg Centre for Re-
generative Therapies, is to use its patented platform technology
to develop and market new t-cell-based regenerative therapies.
The company’s first reference product will be a t-cell product for
kidney transplants. Another interesting start-up is Drug Response
Dx GmbH in Hennigsdorf. DRDx is developing a robust compan-
ion diagnostic test which permits secure stratification regarding
failure in TNF
α blocker (TBA) therapy for rheumatism patients
and therefore addresses a very big market.
The sizes of companies barely changed during the past few years.
Smaller enterprises with less than ten employees make up 63%
of all companies, but these firms also account for only app. 15%
of all employees. More than 54% of those employed in the re-
gional biotech sector work in the 19 companies with more than
50 employees. The thematic focus of the industry also remained
unchanged during recent years and continues lie on biomedicine,
and here particularly diagnostics.
MARCH 2012
10. BIONNALE in Berlin – 10 years of success – Biggest biotech industry meet-
ing in Berlin-Brandenburg celebrates its jubilee
APRIL 2012
NOXXON's NOX-A12 delays recidivation in preclinical glioblastoma model
++++
Epigenomics AG enrolls first participant in its FIT comparative study
with Epi proColon
®
MAY 2012
MOLOGEN AG: Promising start in financial year 2012, quarterly record pre-
sented
++++
ifp and Romer Labs join in world-wide sales cooperation for
EnzymeFast
®
food test kits
JUNE 2012
ORGANOBALANCE presents new research results on ACHEMA 2012: Extend-
ed application range for yeast strains in biotechnological production
++++
CellTrend GmbH and One Lambda Inc. agree to world-wide sales contract
++++
United States Patent and Trademark Office grants co.don AG patent for
production of autologous spinal disc cell transplants
++++
NOXXON initiates
phase IIa study of anti-CCL2/MCP-1 Spiegelmer
®
NOX-E36 for treatment of
diabetic neuropathy
++++
ATLAS Biolabs extends spectrum of services by
Variant AnalysisTM and iReportTM by Ingenuity
®
Systems for data analysis
and interpretation
JULY 2012
Epigenomics appreciates reimbursement of Septin-9 blood test for early rec-
ognition of colon cancer by Swiss Life in France
++++
MOLOGEN AG capital
increase of 22 million Euros
AUGUST 2012
co.don
®
AG reaches another milestone on the path to central approval; Recruit-
ment phase for clinical phase II trial completed successfully
++++
Merck buys
Biochrom AG
++++
Indian pharma firm Piramal invests in molecular imaging
in
Germany
SEPTEMBER 2012
Epigenomics AG announces changes in executive board
++++
Charité and
Sanofi extend partnership by diabetes alliance
++++
MOLOGEN AG: Current
data of kidney cancer therapy MGN1601 shows further improved results
OCTOBER 2012
50 years Klosterfrau Berlin GmbH
++++
ATLAS Biolabs takes part in European
projects on the research of DNA repair and cell aging
++++
co.don
®
AG from
Teltow presents gentle alternative – preserve joints instead of replacing them